• Celcuity (NasdaqCM:CELC) received FDA Priority Review for its New Drug Application for gedatolisib in advanced breast cancer.
• The Priority Review follows strong Phase 3 efficacy results from the VIKTORIA-1 trial in HR-positive, HER2-negative breast cancer.
• An additional Phase 3 readout for the PIK3CA mutant cohort is upcoming and could further influence treatment standards for this patient group.

Celcuity focuses on targeted therapies for cancer, with gedatolisib as a key asset in its pipeline. HR-positive, HER2-negative breast cancer represents a large segment of the breast cancer market, so regulatory progress for this drug draws attention from both clinicians and investors. The combination of Priority Review status and Phase 3 data places the company in the middle of an active area of oncology drug development.

For you as an investor, the current FDA review process and the pending PIK3CA mutant cohort results are important milestones to watch. These events could influence how payers, physicians, and potential partners view Celcuity's position in breast cancer treatment. It is a period in which news flow around trial outcomes and regulatory decisions may play a significant role in shaping sentiment toward NasdaqCM:CELC.

Stay updated on the most important news stories for Celcuity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Celcuity.

The FDA Priority Review for gedatolisib moves Celcuity closer to its first commercial product in HR-positive, HER2-negative advanced breast cancer, a large and competitive market that includes players such as Pfizer, Novartis and Eli Lilly. The strong Phase 3 VIKTORIA-1 efficacy data and participation in the Real-Time Oncology Review program suggest regulators are giving this file focused attention. At the same time, Celcuity reported a full year 2025 net loss of US$177.04 million and continues to have no product revenue, so the company is carrying the cost of late-stage trials and launch build out ahead of any potential sales. The upcoming PIK3CA mutant cohort readout is a key swing factor. If outcomes are clinically meaningful and safety remains manageable, gedatolisib could address a broader slice of the second-line setting. If not, the commercial opportunity could be narrower than management is preparing for. For you as an investor, this news highlights a classic biotech trade-off, with significant market opportunity on one side and ongoing losses and execution risk on the other.

How This Fits Into The Celcuity Narrative

• The Priority Review and VIKTORIA-1 results align with the narrative that gedatolisib could secure an initial indication in second-line HR-positive, HER2-negative advanced breast cancer and begin converting clinical data into product revenue.
• The continued net losses and heavy spend on launch preparation underline one of the narrative risks, that a slower or more limited approval path would extend the period before any earnings leverage appears.
• The upcoming PIK3CA mutant cohort readout, and potential expansion into additional indications such as metastatic castration resistant prostate cancer, add clinical and commercial dimensions that may not be fully reflected in the existing narrative assumptions.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Celcuity to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• Celcuity remains a loss-making, pre revenue company with a 2025 net loss of US$177.04 million, so the path to positive earnings depends heavily on future approvals and uptake of gedatolisib.
• Analysts have flagged that realized revenue and margins could fall short if regulators request more data, payer access is tighter than expected or physician adoption is slower.
• The FDA Priority Review and strong Phase 3 VIKTORIA-1 efficacy results position gedatolisib as a potential new option in a large second-line breast cancer market.
• Management is preparing for a potential 2026 US launch and sees a multibillion-dollar addressable market, which, if partially captured, could materially change Celcuity’s revenue mix over time.

What To Watch Going Forward

From here, keep a close eye on three elements: the FDA’s decision by the July 17, 2026 PDUFA date, the topline PIK3CA mutant cohort data expected in the second quarter of 2026 and any updates on commercialization plans such as partnerships, pricing and payer discussions. These will help you gauge how much of the theoretical opportunity in second-line HR-positive, HER2-negative advanced breast cancer might realistically convert into revenue, and how long Celcuity may need to sustain sizeable losses before reaching a more balanced earnings profile.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Celcuity, head to the community page for Celcuity to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.